Final results of the SAME (Swiss Analysis of Multiple Sclerosis) study comparing four disease-modifying treatments for multiple sclerosis

被引：0
|
作者：
Gobbi, C.
Zecca, C.
Linnebank, M.
Mueller, S.
Meier, R.
Borter, E.
Traber, M.
机构：
[1] Osped Civ, Lugano, Switzerland
[2] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[3] Kantonsspital, St Gallen, Switzerland
[4] Biogen Dompe AG, Zug, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P937
引用
收藏
页码：S422 / S422
页数：1
相关论文
共 50 条
  • [21] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
  • [22] [Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain
    Perez, Alejandro Santiago
    Casado, Santos Esteban
    Payero, Miriam Alvarez
    Pueyo, Angel Escolano
    Bernabe, Angel Guillermo Arevalo
    Zamora, Nuria Padulles
    Ruiz, Pilar Diaz
    Gonzalez, Ana Maria Lopez
    FARMACIA HOSPITALARIA, 2023, 47 (04) : T155 - T160
  • [23] Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients
    Dalla Costa, Gloria
    Finardi, Annamaria
    Garzetti, Livia
    Carandini, Tiziana
    Comi, Giancarlo
    Martinelli, Vittorio
    Furlan, Roberto
    NEUROLOGICAL SCIENCES, 2018, 39 (02) : 373 - 376
  • [24] Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients
    Gloria Dalla Costa
    Annamaria Finardi
    Livia Garzetti
    Tiziana Carandini
    Giancarlo Comi
    Vittorio Martinelli
    Roberto Furlan
    Neurological Sciences, 2018, 39 : 373 - 376
  • [25] Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
    Lebrun, Christine
    Debouverie, Marc
    Vermersch, Patrick
    Clavelou, Pierre
    Rumbach, Lucien
    de Seze, Jerome
    Wiertlevski, Sandrine
    Defer, Gilles
    Gout, Olivier
    Berthier, Frederic
    Danzon, Arlette
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (03) : 399 - 405
  • [26] Disease-modifying treatments in familial and sporadic multiple sclerosis:: Is there any difference?
    Eraksoy, M.
    Ozel, S.
    Turan, N.
    Akman-Demir, G.
    Bilgili, F.
    Topcular, B.
    Ozcan, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 126 - 126
  • [27] Oral disease-modifying treatments for multiple sclerosis - The story so far
    Kieseier, Bernd C.
    Wiendl, Heinz
    CNS DRUGS, 2007, 21 (06) : 483 - 502
  • [28] Can we discontinue disease-modifying treatments in multiple sclerosis patients? No
    Papeix, C.
    REVUE NEUROLOGIQUE, 2017, 173 (1-2) : 41 - 43
  • [29] How should we proceed with disease-modifying treatments for multiple sclerosis?
    Andersson, PB
    Waubant, E
    Goodkin, DE
    LANCET, 1997, 349 (9052): : 586 - 587
  • [30] Discontinuation Of Prolonged Disease-modifying Treatments In Multiple Sclerosis: A Difficult Decision
    Tuncer, A.
    Ozen, P. Acar
    Karabudak, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 65 - 65
12345